Article: Fact check: Resolved lawsuits against Pfizer alleged marketing fraud, data manipulation

Article - Media, Publications

Fact check: Resolved lawsuits against Pfizer alleged marketing fraud, data manipulation

Adrienne Dunn, 19 May 2021

The claim: Pfizer was sued for $2.3 billion for “bribing doctors and suppressing adverse trial results” A viral social media post suggests that Americans shouldn’t trust Pfizer — one of the primary producers of coronavirus vaccines — because of a 2009 lawsuit against the pharmaceutical company.

The April 26 Instagram post claims, “Pfizer got sued for $2,300,000,000 in 2009 for ‘bribing doctors and suppressing adverse trial results.'”

The caption reads, “And you still trust them ?? With your babies ???” The post appears to be referencing a $2.3 billion settlement by Pfizer in 2009, but it’s misleading about the scope of the allegations relating to the settlement. Continue reading “Article: Fact check: Resolved lawsuits against Pfizer alleged marketing fraud, data manipulation”

Letter: Marc Cohodes to Judge Jed Rakoff

Uncategorized

PDF (5 Pages): 20210218-Cohodes Submission Against Petit

“Second, Mr. Cohodes has never engaged in naked short selling (that is, he trades through brokers who find shares for him to borrow and he pays high interest fees to maintain his short positions). He was never part of any concerted illegal campaign to target MiMedx; his actions were his own.”

Comment: The above statement by a lawyer is easily challenged in court with evidence. Mr. Cohodes appears to be panicking. This time around it will cost him 10X to 100X what he was forced to pay Patrick Byrne.  We have it all. The matter of compromised judges and DOJ and SCC as a RICO organization are also on the table. DTCC will not survive a Special Prosecutor.

Article: Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

Article - Media, Publications

Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

Yahoo Finance, 06 January 2021

Daix (France), January 5, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the details of the Phase III clinical trial with its lead drug candidate lanifibranor in NASH following the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA) and the receipt of the Scientific Advice letter from the European Medicines Agency (EMA). The Phase III trial design and clinical strategy have been discussed with both regulatory authorities and the following key points can be confirmed:

Seeking of U.S. accelerated approval and EU conditional approval for lanifibranor to be based on a 72-week histology analysis – Inventiva will seek to obtain accelerated approval in the U.S. and conditional approval in the EU for lanifibranor based on a pre-specified histology analysis in approximately 900 patients after 72 weeks establishing a positive benefit-risk ratio.

Read Full Article

Article: Exuberance Over Good News Drives Bionano Genomics’ Wild Week

Article - Media, Publications

Exuberance Over Good News Drives Bionano Genomics’ Wild Week

John Alford, 04 January 2021

Bionano Genomics, Inc. (BNGO) has been on a wild, meteoric rise in the past few days, and after hours on the 31st it continued to skyrocket, rising to $4 a share. On the 31st of December alone, counting market and after-hours trading, share prices surged $1.90, almost doubling. This capped a wild week, and is a momentum-driven mania trade not based on the previous performance or long-term trend of the company. While recently reporting one good report (via a paid PR service), there are obvious issues surrounding the company to the investor that takes the time to evaluate their most recent 10-Q, recent and potential massive dilution, and decreasing revenue. Continue reading “Article: Exuberance Over Good News Drives Bionano Genomics’ Wild Week”